My most important exposé in years



Daily Market Alert [PREHEADER TEXT — Edit this to control inbox preview] ‌ ‌
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌



Tuesday, August 4, 2026 • Daily Market Alert

You are receiving this email because you are subscribed to Daily Market Alert,
a publication from Behind the Markets.
If you no longer wish to receive these sponsored emails, please unsubscribe
here
<[link removed]>
.




Sponsored Content




1776.



It’s a date that’s burned into our consciousness.



The signing of the Declaration of Independence… the beginning of the Great
American Experiment… and the birth of what would become the richest, most
powerful nation in all of human history.



But what you don’t know is that there is a hidden architecture
<[link removed]> to the story that they don’t teach
you in school.



And of all the prosperity, innovation and freedoms we as Americans enjoy… they
would not exist without twoother tectonic shifts that happened in 1776.



In fact, the world we live in today… it’s all downstream of three events
converging <[link removed]> to unleash the most
explosive period of progress the world has ever seen.



Three separate forces – each of which would’ve been transformative on its own
– but combined… their impact is almost impossible to quantify:



We’re talking, quite literally, hundreds of trillions of dollars in wealth
creation… hundred of millions lifted from poverty… the rise of new political,
social, and economic systems.



And, of course, the creation of some of the world’s greatest fortunes…
towering financial dynasties that have endured for centuries.



All of it can be traced back to 1776 and the convergence of these three forces.



Now, on the eve of America’s 250th anniversary, I believe that we are standing
on thethreshold of a new 1776 moment. <[link removed]>



A second convergence of forces across the three domains that dictate almost
every aspect of your life:Economics. Technology. Politics.



This is something we have not seen in two and half centuries… a true
once-in-a-generation paradigm shift that could trigger the greatest transfer of
wealth in American history.



Three Nobel Prize winners have already sounded the alarm.



McKinsey has estimated it could be worth $25 trillion annually.



But unlike 1776, this isn’t some slow-moving shift that will play out over
decades. No. It’salready deciding who gets ahead and who falls behind.



And as you’ll discover today, the aftershock of this convergence could “reset”
not just your personal wealth, but the entire U.S. economic system:



How you work, how you vote, how you protect and build your wealth… it’s all
being turned upside down by what one famous Stanford economist says is:



“The biggest change ever… bigger than electricity… bigger than the steam
engine.”



And almost nobody is prepared for it.



But that ends now. I’m laying out the full story for you.



Watch America’s Next 1776 Moment now to ensure you’re on the winning side.



➡ Click here to stream it at no cost. <[link removed]>



Good investing,



Porter Stansberry

Full Story > <[link removed]>

 


Suggested Reading by Morning Watchlist from Behind the Markets:

Four Trades Wall Street Is Still Misreading

The Bill Always Arrives. Four Places It's Being Delivered Right Now.

Wall Street loves a green tape. It lets everyone pretend the economy is
healing in a straight line.

It isn't. The data are splitting into winners and losers: consumers are
getting more selective, housing is stuck behind the mortgage lock-in, and
private credit is discovering that "private" does not mean "immune."

That is where independent investors have an advantage. You do not need the
consensus story. You need to find the pressure point before it becomes a
headline. Today: four pressure points, each verified against the primary
numbers — and three companies standing on the right side of them.

1) Biotech's Real Risk Is Not the FDA. It's Reimbursement.

Myriad Genetics was one of the market's hardest-hit diagnostics names after
its second-quarter report — and the numbers deserve their full weight. Revenue
fell 11% year over year to $190.7 million — missing estimates by roughly $15
million — as test volume declined just 1% while average revenue per test fell
9%, prompting management to slash full-year revenue guidance to $770–790
million from $860–880 million and suspend adjusted-EBITDA guidance entirely.
The market's verdict was brutal: the stock plunged as much as 37.8% after
hours, from $5.37 toward $3.34. Read the anatomy carefully: demand did not
collapse — the cancer business grew volumes 6%, and the mental-health franchise
reached a record 40,000-plus ordering clinicians — it was payer-driven
reimbursement friction, lower prior-period collections, and an $11 million
write-off of aged receivables that did the damage. The test worked. Getting
paid for the test didn't.

That's the special situation we're seeing right now — a real franchise with a
reimbursement problem — and with street targets now spanning $4 to $10, the
bargain hunters will circle. Our position: watch-the-execution, not
buy-the-dip, until payer collections stabilize. But here's the investable flip
side of the exact same thesis, proven in the exact same earnings season:

Company: Quest Diagnostics (SYM: DGX)The scale lab with the payer leverage
Myriad lacks — same industry, same reimbursement environment, opposite outcome.

One week before Myriad's disaster, Quest reported the mirror image: revenue
up 10.2% to $3.04 billion with 10% organic growth across every major channel —
physicians, hospitals, and consumers — adjusted EPS of $3.12 versus the $2.83
consensus, and full-year guidance raised on both lines (to $11.95–12.05 billion
in revenue and $11.05–11.25 in EPS), sending the stock to a fresh 52-week high.
Why does Quest thrive in the payer environment that's strangling Myriad? Scale
is the reimbursement moat: national contracts, billing infrastructure a
specialty lab can't match, and revenue per requisition rising 2.9% on a mix
shift toward high-value advanced diagnostics — plus it's now expanding into
Myriad's precision-oncology turf, wiring its Haystack MRD cancer-monitoring
test into oncology health records reaching 4,700 clinicians.

The honest file: the discovery premium is real — the stock, around $228, sits
at its highs after the run, with street targets averaging in the $226–239 range
(Jefferies at $245, Leerink $244, Baird Neutral at $236) — you're buying
quality at fair price, not a discount, though at 23.8x earnings it's still
cheaper than its healthcare peers and one DCF pegs fair value far higher. And
the sector risk cuts at everyone eventually: Barclays flagged HCA's disclosure
of lost Affordable Care Act coverage as a negative utilization read-through for
both Quest and Labcorp. Fewer insured patients means fewer tests —
reimbursement risk wearing a different mask. Earnings risk passed July 23.

Bottom line: In diagnostics, the moat is not the test. It is getting paid for
the test — and one earnings season just proved it in both directions.

2) The Consumer Is Not Dead. It Is Trading Down.

The headline says consumer confidence improved — the July Michigan sentiment
bounce is a bounce, not a victory lap — while the Beige Book's fine print says
lower-income households are prioritizing value and trading down, retail sales
ex-autos slipped, and consumer credit decelerated sharply.

Consumers are still buying. They're making fewer mistakes. That's a barbell —
and the value side of the barbell has a king.

Company: Ross Stores (SYM: ROST)The purest trade-down machine in retail — 30%
of the off-price market, a 17% comp quarter, and one honest problem: the market
got here first.

Ross is the thesis in retail form: roughly 30% of the domestic off-price
apparel market across more than 2,100 stores, built on value leadership and
closeout buying power smaller rivals can't replicate — and its dd's DISCOUNTS
chain serves precisely the lower-income shopper the Beige Book describes. The
proof arrived in May: a blowout quarter with 17% comparable sales growth and a
raised full-year comp outlook of 6–7%, jumping the stock 15.8% in a day. When
the trade-down wave hit, Ross caught all of it. Morningstar's own bull scenario
— higher-income households permanently shifting to off-price — is arguably
already happening.

Now the price of admission, stated plainly: the stock trades around $233, up
82% over the past year, at 34.8x earnings — far above industry averages — and
the street has begun stepping aside on valuation alone: Wells Fargo downgraded
to Equal Weight citing the re-rating, JPMorgan trimmed its target, and the
19-analyst average target of $256 offers only about 9.5% upside. This is
proof-of-thesis, not a bargain — the honest play is owning it as a core barbell
holding through the cycle, or waiting for the next earnings wobble (Q2 lands in
roughly three weeks). Tariff-driven cost pressure and the law of large numbers
are the standing risks.

Bottom line: A consumer rebound built on discounts is not broad strength. Own
the value side — and know that the value side now trades at a premium, which
tells you how right the thesis has been.

3) Housing's "Recovery" Is Really a Supply Freeze.

Mortgage rates climbed again — 6.66% on the 30-year with applications down
6.4% in the July 24 week, and new homes selling at their biggest discount to
existing homes since 1968 — while lock-in keeps resale inventory frozen.
Unaffordable and undersupplied, simultaneously. That's not a recovery; it's a
fight over who absorbs the payment shock.

The investable angle is separating toll collectors from volume victims. Two
weeks ago we featured the biggest landlord of the frozen-out. Today, its
sibling — with a twist.

Continue Reading →
<[link removed]>


At Daily Market Alert <[link removed]>
, our priority is delivering insightful perspectives on the financial landscape
straight to our audience.The content above is an important message from one of
our highly valued sponsors.






This email is sent on behalf of Daily Market Alert, a Behind the Markets LLC
("the Company") publication, including its managers, employees, and assigns.
The Company does not provide any guarantee or warranty regarding the accuracy
or reliability of the information advertised herein.

The Company is not affiliated with any specific security mentioned in this
email, nor does it receive compensation from any such entity

Please be advised that the Company is not registered or licensed by any
governing body in any jurisdiction to offer investment advice or
recommendations.

None of the content in this email should be construed as personalized
financial advice. Any investment decisions made based on the information
provided should be done so only after consulting with a qualified investment
advisor and conducting a thorough review of the relevant prospectus or
financial statements

You are receiving this because you signed up for the Daily Market Alert
newsletter.

Daily Market Alert is a Behind the Markets <[link removed]>
Publication.

Behind the Markets, LLC

4260 NW 1st Ave #55, Boca Raton, FL.

Unsubscribe
<[link removed]>
Terms of Use <[link removed]> Privacy Policy
<[link removed]>